GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often...

Full description

Bibliographic Details
Main Authors: Riccardo Di Fiore, Sherif Suleiman, Bridget Ellul, Sharon A. O’Toole, Charles Savona-Ventura, Ana Felix, Valerio Napolioni, Neil T. Conlon, Ayse Elif Erson-Bensan, Ilker Kahramanoglu, Miriam J. Azzopardi, Miriam Dalmas, Neville Calleja, Mark R. Brincat, Yves Muscat-Baron, Maja Sabol, Vera Dimitrievska, Angel Yordanov, Mariela Vasileva-Slaveva, Kristelle von Brockdorff, Rachel A. Micallef, Paul Kubelac, Patriciu Achimas-Cadariu, Catalin Vlad, Olga Tzortzatou, Robert Poka, Antonio Giordano, Alex Felice, Nicholas Reed, C. Simon Herrington, David Faraggi, Jean Calleja-Agius
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
rare gynecologic tumors
circulating tumor-specific markers
cancer stem cells
theranostics
biobanking
personalized medicine
Online Access:https://www.mdpi.com/2072-6694/13/3/493

Internet

https://www.mdpi.com/2072-6694/13/3/493

Similar Items